How are doctors using faricimab (Vabysmo, Genentech/Roche) in real-world settings? The IRIS Registry has a few answers. We sat down with Durga Borkar, MD, MMCi, to hear what researchers in the FARETINA-AMD study group found regarding dynamics related to faricimab’s use in wet AMD patients since its approval in January of last year. 

We also interviewed Varun Chaudhary, MD, to learn specifically about faricimab treat-and-extend regimens in wet AMD patients who were enrolled in TENAYA and LUCERNE. How many patients achieved treatment intervals of 12 or 16 weeks?